Wolters Kluwer UptoDate Lexidrug

Name: Wolters Kluwer UptoDate Lexidrug
Brand: Wolters Kluwer
Rating: 4.8 (118 reviews)

Wolters Kluwer UpToDate Lexidrug is a referential drug information and medication decision-support platform that provides clinician-grade drug monographs, dosing and interaction checking, and IV compatibility and related clinical tools.

Est 1836|Valuation $19.4B|Raised $840K

LinkedIn 357K|Website|Web traffic 3.0M|FTEs 21,000|HQ Alphen aan den Rijn, Netherlands

Wolters Kluwer UptoDate Lexidrug screenshot

01Competitive Landscape

Narrative competitive analysis

Where Lexidrug appears to provide value based on accessible evidence: - Depth of content for pharmacists, including IV compatibility and detailed monographs, is frequently cited in practitioner discussions as a reason to use the product. - It is commonly sold alongside UpToDate and is present in many training and hospital environments. Where alternatives may provide advantages: - Epocrates and Medscape: lower-cost or free tiers suitable for basic outpatient lookups and quick references. - Elsevier Clinical Pharmacology: potential advantages for organizations already standardized on Elsevier tools; may offer different search and integration experiences. - Micromedex: preferred by some pharmacists for its organization or specific modules depending on institutional needs.

Market adoption signals

Android install counts indicate wide distribution but do not prove paid institutional adoption.
Wolters Kluwer has indicated integration of Lexidrug content into machine-assisted decision tools, reflecting ongoing product investment and potential future changes to workflow and packaging.

	UpToDate Lexidrug	Merative Micromedex	Elsevier Clinical Pharmacology (ClinicalKey)
Starting Price	Public pricing varies; published per-seat pricing is available from the vendor and reseller annual pricing examples appear in some sources (directional).	Pricing typically enterprise/quote-based; public starting price not found in this research run.	Individual subscription options exist; enterprise pricing typically quote-based and not fully captured here.
Best For	Institutions that require detailed monographs, interaction checking, and IV compatibility in selected packages; organizations that already use UpToDate.	Organizations that require Micromedex suite components (e.g., POISINDEX, DRUGDEX, IV comp).	Organizations standardized on Elsevier products who value integration with ClinicalKey and Elsevier evidence workflows.
Key Strength	Broad set of clinician-focused drug reference tools and hospital-oriented modules in selected packages.	Established drug database with multiple specialized modules.	Integration with Elsevier content ecosystem and ClinicalKey search features.
Key Weakness	Reported pricing concerns and packaging complexity; mobile entitlement friction for some institutions.	Mobile access and pricing transparency may be restrictive in some cases.	Pricing transparency and module alignment with specific inpatient tools may require validation.

01Competitive Landscape

Narrative competitive analysis

Where Lexidrug appears to provide value based on accessible evidence:

Depth of content for pharmacists, including IV compatibility and detailed monographs, is frequently cited in practitioner discussions as a reason to use the product.
It is commonly sold alongside UpToDate and is present in many training and hospital environments.

Where alternatives may provide advantages:

Epocrates and Medscape: lower-cost or free tiers suitable for basic outpatient lookups and quick references.
Elsevier Clinical Pharmacology: potential advantages for organizations already standardized on Elsevier tools; may offer different search and integration experiences.
Micromedex: preferred by some pharmacists for its organization or specific modules depending on institutional needs.

Market adoption signals

Android install counts indicate wide distribution but do not prove paid institutional adoption.
Wolters Kluwer has indicated integration of Lexidrug content into machine-assisted decision tools, reflecting ongoing product investment and potential future changes to workflow and packaging.

	UpToDate Lexidrug	Merative Micromedex	Elsevier Clinical Pharmacology (ClinicalKey)
Starting Price	Public pricing varies; published per-seat pricing is available from the vendor and reseller annual pricing examples appear in some sources (directional).	Pricing typically enterprise/quote-based; public starting price not found in this research run.	Individual subscription options exist; enterprise pricing typically quote-based and not fully captured here.
Best For	Institutions that require detailed monographs, interaction checking, and IV compatibility in selected packages; organizations that already use UpToDate.	Organizations that require Micromedex suite components (e.g., POISINDEX, DRUGDEX, IV comp).	Organizations standardized on Elsevier products who value integration with ClinicalKey and Elsevier evidence workflows.
Key Strength	Broad set of clinician-focused drug reference tools and hospital-oriented modules in selected packages.	Established drug database with multiple specialized modules.	Integration with Elsevier content ecosystem and ClinicalKey search features.
Key Weakness	Reported pricing concerns and packaging complexity; mobile entitlement friction for some institutions.	Mobile access and pricing transparency may be restrictive in some cases.	Pricing transparency and module alignment with specific inpatient tools may require validation.

Wolters Kluwer UptoDate Lexidrug

01Competitive Landscape

Narrative competitive analysis

Market adoption signals

02Market Map

01Competitive Landscape

Narrative competitive analysis

Market adoption signals

02Market Map